Literature DB >> 8116615

Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes.

D Isbrandt1, G Arlt, D A Brooks, J J Hopwood, K von Figura, C Peters.   

Abstract

Mucopolysaccharidosis type VI, or Maroteaux-Lamy syndrome, is a lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase B (ASB), also known as N-acetylgalactosamine-4-sulfatase. Multiple clinical phenotypes of this autosomal recessively inherited disease have been described. Recent isolation and characterization of the human ASB gene facilitated the analysis of molecular defects underlying the different phenotypes. Conditions for PCR amplification of the entire open reading frame from genomic DNA and for subsequent direct automated DNA sequencing of the resulting DNA fragments were established. Besides two polymorphisms described elsewhere that cause methionine-for-valine substitutions in the arylsulfatase B gene, six new mutations in six patients were detected: four point mutations resulting in amino acid substitutions, a 1-bp deletion, and a 1-bp insertion. The point mutations were two G-to-A and two T-to-C transitions. The G-to-A transitions cause an arginine-for-glycine substitution at residue 144 in a homoallelic patient with a severe disease phenotype and a tyrosine-for-cysteine substitution at residue 521 in a potentially heteroallelic patient with the severe form of the disease. The T-to-C transitions cause an arginine-for-cysteine substitution at amino acid residue 192 in a homoallelic patient with mild symptoms and a proline-for-leucine substitution at amino acid 321 in a homoallelic patient with the intermediate form. The insertion between nucleotides T1284 and G1285 resulted in a loss of the 100 C-terminal amino acids of the wild-type protein and in the deletion of nucleotide C1577 in a 39-amino-acid C-terminal extension of the ASB polypeptide. Both mutations were detected in homoallelic patients with the severe form of the disease. Expression of mutant cDNAs encoding the four amino acid substitutions and the deletion resulted in severe reduction of both ASB protein levels and arylsulfatase enzyme activity in comparison with a wild-type control. The six mutations described in the present study were unique among 25 unrelated mucopolysaccharidosis VI patients, suggesting a broad molecular heterogeneity of the Maroteaux-Lamy syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8116615      PMCID: PMC1918135     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  22 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Structure of the human arylsulfatase B gene.

Authors:  S Modaressi; K Rupp; K von Figura; C Peters
Journal:  Biol Chem Hoppe Seyler       Date:  1993-05

3.  The sulphatase of ox liver. XI. The isoelectric focussing of a purified preparation of sulphatase B.

Authors:  E Allen; A B Roy
Journal:  Biochim Biophys Acta       Date:  1968-10-21

4.  Mucopolysaccharidosis type VI: identification of three mutations in the arylsulfatase B gene of patients with the severe and mild phenotypes provides molecular evidence for genetic heterogeneity.

Authors:  W D Jin; C E Jackson; R J Desnick; E H Schuchman
Journal:  Am J Hum Genet       Date:  1992-04       Impact factor: 11.025

5.  Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B.

Authors:  G Wicker; V Prill; D Brooks; G Gibson; J Hopwood; K von Figura; C Peters
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

6.  Human N-acetylgalactosamine-4-sulphatase: protein maturation and isolation of genomic clones.

Authors:  T Litjens; C P Morris; G J Gibson; K R Beckmann; J J Hopwood
Journal:  Biochem Int       Date:  1991-05

7.  A common polymorphism in the human arylsulfatase B (ARSB) gene at 5q13-q14.

Authors:  W D Jin; R J Desnick; E H Schuchman
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

8.  An N-acetylgalactosamine-4-sulfatase mutation (delta G238) results in a severe Maroteaux-Lamy phenotype.

Authors:  T Litjens; C P Morris; E F Robertson; C Peters; K von Figura; J J Hopwood
Journal:  Hum Mutat       Date:  1992       Impact factor: 4.878

9.  Phylogenetic conservation of arylsulfatases. cDNA cloning and expression of human arylsulfatase B.

Authors:  C Peters; B Schmidt; W Rommerskirch; K Rupp; M Zühlsdorf; M Vingron; H E Meyer; R Pohlmann; K von Figura
Journal:  J Biol Chem       Date:  1990-02-25       Impact factor: 5.157

10.  Human arylsulfatase B: MOPAC cloning, nucleotide sequence of a full-length cDNA, and regions of amino acid identity with arylsulfatases A and C.

Authors:  E H Schuchman; C E Jackson; R J Desnick
Journal:  Genomics       Date:  1990-01       Impact factor: 5.736

View more
  25 in total

1.  Role of LAMP-2 in lysosome biogenesis and autophagy.

Authors:  Eeva-Liisa Eskelinen; Anna Lena Illert; Yoshitaka Tanaka; Günter Schwarzmann; Judith Blanz; Kurt Von Figura; Paul Saftig
Journal:  Mol Biol Cell       Date:  2002-09       Impact factor: 4.138

2.  Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients.

Authors:  T Litjens; D A Brooks; C Peters; G J Gibson; J J Hopwood
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

3.  Mucopolysaccharidosis type VI: Identification of novel mutations on the arylsulphatase B gene in South American patients.

Authors:  M F G Petry; K Nonemacher; J C Sebben; I V D Schwartz; A C M Azevedo; M G Burin; A R de Rezende; C A Kim; R Giugliani; S Leistner-Segal
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

4.  Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis.

Authors:  W Halangk; M M Lerch; B Brandt-Nedelev; W Roth; M Ruthenbuerger; T Reinheckel; W Domschke; H Lippert; C Peters; J Deussing
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

5.  Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series.

Authors:  Anke Thümler; Elke Miebach; Christina Lampe; Susanne Pitz; Wolfgang Kamin; Christoph Kampmann; Bianca Link; Eugen Mengel
Journal:  J Inherit Metab Dis       Date:  2012-03-23       Impact factor: 4.982

6.  Identification of a novel arylsulfatase B gene mutation in three unrelated Iranian mucopolysaccharidosis type-VI patients with different phenotype severity.

Authors:  Nayerossadat Nouri; Nargesossadat Nouri; Omid Aryani; Behnam Kamalidehghan; Massoud Houshmand
Journal:  Iran Biomed J       Date:  2012

7.  Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI.

Authors:  M Evers; P Saftig; P Schmidt; A Hafner; D B McLoghlin; W Schmahl; B Hess; K von Figura; C Peters
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

8.  Dried blood spots allow targeted screening to diagnose mucopolysaccharidosis and mucolipidosis.

Authors:  Paulina Nieves Cobos; Cordula Steglich; René Santer; Zoltan Lukacs; Andreas Gal
Journal:  JIMD Rep       Date:  2014-05-06

Review 9.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

10.  Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

Authors:  E Voskoboeva; D Isbrandt; K von Figura; X Krasnopolskaya; C Peters
Journal:  Hum Genet       Date:  1994-03       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.